艾拉莫德联合甲氨蝶呤对类风湿关节炎患者炎症因子水平及安全性的影响

Effect of eramode combined with methotrexate on inflammatory factors and safety in patients with rheumatoid arthritis

目的探讨艾拉莫德联合甲氨蝶呤对类风湿关节炎患者炎症因子水平及安全性的影响。方法选取2019年8月至2020年8月本院收治的86例类风湿关节炎患者作为研究对象,按照随机数字表法分为对照组与研究组,每组43例。对照组给予甲氨蝶呤治疗,研究组予以艾拉莫德联合甲氨蝶呤治疗,比较两组临床疗效、血清炎症因子及不良反应发生情况。结果研究组治疗总有效率为97.67%,高于对照组的79.07%,差异有统计学意义(P<0.05)。治疗后,两组环氧合酶(COX-2)、巨噬细胞集落刺激因子(M-CSF)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论艾拉莫德联合甲氨蝶呤可改善类风湿关节炎患者机体炎症反应,促进关节功能恢复,且安全可靠。

Objective To investigate the effects of eramod combined with methotrexate on inflammatory factors and safety in patients with rheumatoid arthritis.Methods A total of 86 patients with rheumatoid arthritis admitted to our hospital from August 2019 to August 2020 were selected as the research subjects,and they were divided into the control group and the study group according to random number table method,with 43 cases in each group.The control group was treated with methotrexate,and the study group was treated with eramod combined with methotrexate,the clinical efficacy,serum inflammatory factors and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate in the study group was 97.67%,which was higher than 79.07%in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of cyclooxygenase-2(COX-2),macrophage colony stimulating factor(M-CSF),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)of the two groups were lower than those before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Eramode and methotrexate can improve the inflammatory response of patients with rheumatoid arthritis and promote the recovery of joint function,and it is safe and reliable.